Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × PT-100 dipeptide × Clear all
NCT00116389 2007-06-08

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Point Therapeutics

Phase 2 Terminated
60 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT00243204 2007-06-08

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Point Therapeutics

Phase 3 Terminated
400 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡